Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesDesignation granted for warm autoimmune ...
Three months of dual antiplatelet therapy after PCI may safely balance thrombosis and bleeding risk in both patients with low ...
Sean Manaea certainly won’t return to pitch for the Mets in April, as originally hoped. Now May isn’t looking so good for him ...
6d
FDA Approval: The FDA granted full approval for Symvess on December 19, 2024 for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid ...
1d
Giancarlo Stanton embraced the torpedo bats long before they became the talk of MLB. The Yankees slugger used the bowling-pin-shaped bats last season, including during a torrid playoff run in which he ...
The strands of fibrin bind the platelets together and essentially tighten the clot to make it stable. The clotting mechanism also can cause clots to form in ways that are harmful—a condition called ...
FDA Grants Orphan Drug Status to Sanofi’s Rilzabrutinib: A New Hope for wAIHA, IgG4-RD, and Beyond
Rilzabrutinib, an investigational oral BTK inhibitor, has received orphan drug designation from the FDA for treating warm autoimmune hemolytic an ...
A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's ...
With two high-profile NBA stars suffering from blood clots recently, we asked doctors how they happen and if they are ...
Blood clots are associated with life-threatening conditions such as sepsis, sickle cell disease, heart attack, and stroke.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback